Pain Management for Patients on Celebrex and Tizanidine

Introduction to Pain Management

The American College of Physicians and other guideline societies recommend avoiding the addition of another NSAID to a patient's existing celecoxib regimen, as this significantly increases the risk of serious adverse events, including additive gastrointestinal toxicity, compounded renal toxicity, and enhanced cardiovascular risk 1

For patients requiring rapid pain relief, the National Comprehensive Cancer Network recommends initiating short-acting opioids with rapid titration according to pain severity, and calculating 10-20% of any previous 24-hour opioid requirement if the patient is opioid-tolerant 4
The National Comprehensive Cancer Network also suggests reassessing efficacy at 60 minutes for oral opioids, and increasing the dose by 50-100% if pain is unchanged, or continuing the same dose as needed 4

The Journal of the National Comprehensive Cancer Network recommends reassessing pain intensity at each contact using a numerical rating scale (0-10), and monitoring for adverse effects including nausea, dizziness, drowsiness, and constipation with tramadol 4
The Praxis Medical Insights guideline recommends monitoring for contraindications to tramadol, including seizure history, respiratory compromise, and liver/renal impairment before prescribing, and providing a written pain plan including all medications, dosing instructions, potential side effects, and specific instructions for when to call the provider 1, 4, 5

The Praxis Medical Insights guideline warns against adding a second NSAID (ibuprofen, naproxen, ketorolac) to existing celecoxib therapy, due to the increased risk of adverse events 1
The guideline also recommends assessing for contraindications to tramadol, including seizure history, respiratory compromise, and liver/renal impairment before prescribing 1